Abstract

* Albiglutide (Tanzeum), a glucagon-like peptide-1 agonist, has been approved by the FDA for the treatment of type 2 diabetes.

* Patients who have a personal or family history of medullary thyroid carcinoma shouldn't be prescribed albiglutide.